IMUNON's earnings call highlighted significant progress in its ovarian cancer treatment and the strong start of the Phase III OVATION 3 trial. The company is effectively managing costs and enhancing shareholder value through a stock dividend. However, it faces challenges in the capital markets, requiring ongoing efforts to secure additional funding.

Company Guidance

During the call, IMUNON provided detailed guidance on the progress and future plans for its lead candidate, IMNN-001, a gene-mediated IL-12 therapy for ovarian cancer. The OVATION 2 study showed a median increase in overall survival of 13 months, with a 45% improvement compared to the standard of care alone, and a hazard ratio of 0.69. The use of PARP inhibitors further enhanced outcomes, with median overall survival not yet reached in the IMNN-001 treatment arm after more than five years. The Phase III OVATION 3 trial is underway, with a primary endpoint of overall survival and secondary endpoints including surgical response score, chemotherapy response score, and time to second-line treatment. The trial began with three activated sites and has already randomized and treated its first patient. The company announced a strategy to fund OVATION 3 through partnerships and equity, and recently raised over $3 million through warrant exercises and ATM sales, while also implementing cost-saving measures to extend its cash runway.

Significant Improvement in Ovarian Cancer Treatment

IMUNON's IMNN-001 therapy showed a median increase in overall survival of 13 months, a 45% improvement, in ovarian cancer patients when combined with standard care chemotherapy.

Phase III OVATION 3 Trial Progress

The OVATION 3 trial has had a strong start, opening sites faster than industry benchmarks, and has already enrolled its first patient. The trial is poised to redefine treatment for advanced ovarian cancer.

Stock Dividend to Enhance Shareholder Value

IMUNON announced a 15% stock dividend to boost shareholder value and confidence in the company's growth potential.

Cost Reduction and Financial Management

Operating expenses declined significantly, with R&D expenses dropping from $2.8 million to $1.2 million, and G&A expenses from $2.2 million to $1.5 million.

Imunon (IMNN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMNN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-1.48 / -	-4.435	―	―	―
Aug 05, 2025	2025 (Q2)	-4.14 / -1.87	-6.652	71.89% (+4.78)	―
May 12, 2025	2025 (Q1)	-4.57 / -3.65	-6.783	46.16% (+3.13)	―
Feb 27, 2025	2024 (Q4)	-4.67 / -3.26	-6.522	50.00% (+3.26)	―
Nov 07, 2024	2024 (Q3)	-5.06 / -4.43	-4.826	8.10% (+0.39)	―
Aug 14, 2024	2024 (Q2)	-7.04 / -6.65	-7.957	16.40% (+1.30)	―
May 13, 2024	2024 (Q1)	-7.39 / -6.78	-8.87	23.53% (+2.09)	―
Mar 28, 2024	2023 (Q4)	-7.65 / -6.52	-19.174	65.99% (+12.65)	―
Nov 14, 2023	2023 (Q3)	-8.61 / -4.83	-11.348	57.47% (+6.52)	―
Aug 10, 2023	2023 (Q2)	-9.20 / -7.96	-11.348	29.88% (+3.39)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IMNN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$8.00	$7.62	-4.75%
May 12, 2025	$10.43	$10.64	+2.01%
Feb 27, 2025	$10.49	$10.56	+0.67%
Nov 07, 2024	$12.22	$10.72	-12.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Imunon (IMNN) report earnings?

Imunon (IMNN) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).

What is Imunon (IMNN) earnings time?

Imunon (IMNN) earnings time is at Nov 17, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IMNN EPS forecast?

IMNN EPS forecast for the fiscal quarter 2025 (Q3) is -1.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing